Chronic inflammatory demyelinating polyneuropathy (CIDP) is one of the few conditions for which intravenous immunoglobulin (IVIG) carries an FDA-approved indication rather than off-label use. The dose, schedule and infusion rate for CIDP are printed in the prescribing information of specific, named products.
This article covers what the FDA-approved labels and the 2021 EAN/PNS CIDP guideline say about IVIG dosing in CIDP, why a loading course runs across consecutive days, which adverse reactions the CIDP trials recorded, and what a health plan asks for. Prime Infusions operates 13 infusion centers across New York and delivers CIDP infusions in the ambulatory setting described on our IVIG treatment page.
What is CIDP, and which immunoglobulin products are FDA-approved to treat it?
CIDP is an acquired autoimmune disorder of the peripheral nervous system in which the immune system attacks the myelin sheath insulating peripheral nerves, producing weakness and sensory loss that develops over months rather than days. GBS|CIDP Foundation International describes IVIG as "the only drug that has FDA, Canadian, and European approval for treatment of CIDP."
Five intravenous immunoglobulin products carry an FDA-approved indication for CIDP in adults: Gamunex-C, Gammaked, Privigen, Panzyga and Gammagard Liquid. On the Gamunex-C and Gammaked labels, primary humoral immunodeficiency may be treated either intravenously or subcutaneously, but CIDP is an intravenous indication only.
Two subcutaneous immunoglobulin products carry a narrower CIDP indication limited to maintenance. Hizentra is labeled for CIDP "as maintenance therapy to prevent relapse," and HyQvia was approved by the FDA on January 16, 2024 for CIDP maintenance therapy in adults. Neither subcutaneous product is labeled for the initial loading course.
How is IVIG dosed for CIDP, and how does loading differ from maintenance?
IVIG dosing in CIDP is weight-based and splits into two phases. The loading dose, also called induction, totals 2 g/kg. Maintenance is commonly 1 g/kg repeated every three weeks. The 2021 EAN/PNS guideline on CIDP (Van den Bergh and colleagues, European Journal of Neurology) states that "the usual total IVIg dose is 2 g/kg, divided over 2 to 5 days," and that "the most commonly used IVIg maintenance regimen in clinical trials is 1 g/kg every 3 weeks, but in clinical practice lower doses and longer treatment intervals... should be considered (eg, 0.4-1 g/kg every 2-6 weeks)."
The same EAN/PNS guideline states that "both IVIg and oral or IV corticosteroids are first-line treatments for CIDP," so IVIG is not the only first-line option and the choice belongs to the treating neurologist. Because every dose is calculated in mg/kg, Medicare documentation guidance requires a weight in kilograms recorded before each infusion.
| Product | Labeled CIDP loading dose | Labeled CIDP maintenance dose |
|---|---|---|
| Gamunex-C | 2 g/kg | 1 g/kg every 3 weeks |
| Privigen | 2 g/kg over 2 to 5 days | 1 g/kg every 3 weeks |
| Panzyga | 2 g/kg | 1 to 2 g/kg every 3 weeks |
| Gammagard Liquid | 2 g/kg over 2 to 5 days (induction) | 1 g/kg every 3 weeks, over 1 to 4 days |
Is the CIDP loading dose given in one visit or across consecutive days?
A CIDP loading course is delivered across consecutive days, not in a single long visit. The Privigen label prescribes the 2 g/kg loading dose "over 2-5 days" and the Gammagard Liquid label prescribes induction of "2 g/kg over 2-5 days." The reason is volume: for a 70 kg adult, 2 g/kg is 140 grams of immunoglobulin, roughly 1,400 mL of a 10% product. Dividing that total across days is a labeled instruction, not a scheduling convenience.
Anyone starting IVIG for CIDP should plan for a block of two to five consecutive appointments and arrange transportation and time away from work accordingly. Maintenance has a different shape: the Gammagard Liquid label allows the 1 g/kg maintenance dose to be given "over 1-4 days," so a maintenance cycle is often one or two visits every three weeks rather than a week-long block. The number of days on any course is set by the prescriber order and the product selected.
How long does each CIDP infusion take, and why is the first one longer?
The Immune Deficiency Foundation states that IVIG infusions "typically... take between 2-6 hours." A first infusion sits at the longer end of that range because every immunoglobulin label prescribes stepwise rate escalation, increasing only if tolerated. For CIDP, the Gamunex-C label specifies a starting rate of 2 mg/kg/min increasing to a maximum of 8 mg/kg/min, and the Panzyga label specifies 1 mg/kg/min rising to a maximum of 12 mg/kg/min.
The Immune Deficiency Foundation also states that "a first-time administration rate should be slower than recommended and then increased to a rate that is tolerable." Intake paperwork, a documented weight, baseline vital signs and IV access add further time to a first CIDP visit. Our guide to a first IVIG infusion covers preparation in more detail.
What side effects were reported with IVIG in the CIDP trial population?
The Gamunex-C prescribing information lists adverse reactions from the trial supporting its CIDP indication. In that CIDP population, headache was reported in 31.0% of patients, pyrexia in 13.3%, hypertension in 8.8%, chills in 8.0%, nausea in 6.2%, rash in 6.2%, arthralgia in 5.3% and asthenia in 5.3%. The same label reports headache in 14.9% of patients at the lower replacement doses used for immunodeficiency, which shows reaction rates tracking the higher immunomodulatory doses used in CIDP.
Every IVIG product carries an FDA boxed warning headed "WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE." That boxed warning states that thrombosis "may occur in the absence of known risk factors" and directs that patients at risk be given IVIG "at the minimum dose and infusion rate practicable" with adequate hydration beforehand. Hypersensitivity, aseptic meningitis syndrome, hemolysis, hyperproteinemia and transfusion-related acute lung injury appear in Section 5, Warnings and Precautions, and are not part of the boxed warning. The Immune Deficiency Foundation advises drinking water the day before, the day of and the day after an infusion, and lists acetaminophen, diphenhydramine, non-steroidal anti-inflammatory drugs and corticosteroids among premedications a clinician may consider.
What does a health plan require before approving IVIG for CIDP?
Commercial plans require precertification for IVIG, and the CIDP criteria are specific. Aetna Clinical Policy Bulletin 0206 on parenteral immunoglobulins, last reviewed June 18, 2026, requires for initial CIDP approval that the "disease course is progressive or relapsing/remitting for 2 months or longer," that there is "moderate to severe functional disability," and that the diagnosis is "confirmed by electrodiagnostic studies." For continuation, the same bulletin requires "significant improvement in disability and maintenance of improvement" at the "lowest effective dose and frequency." Coverage is determined by each patient plan; the Prime Infusions team verifies benefits and submits the authorization request.
Documents worth having ready are the electrodiagnostic report, the ICD-10 diagnosis, a note establishing a disease course of two months or longer with current functional disability, weight in kilograms, and an order naming product, dose, rate and frequency. Where a plan applies step therapy, New York Insurance Law section 4903 requires an override determination within 72 hours of receipt of the supporting information, or within 24 hours where delay would put the health of the insured in serious jeopardy. Our article on IVIG prior authorization in New York works through the paperwork in order.
Where can a patient get IVIG for CIDP in New York?
Prime Infusions operates 13 infusion centers across New York, which matters for CIDP because a loading course means several visits inside one week and maintenance means returning every few weeks. Locations include the Brooklyn infusion center on Foster Avenue and a second Brooklyn center in Boro Park; four Queens centers, among them the Fresh Meadows infusion center plus Astoria, Howard Beach and Jamaica; the Upper East Side of Manhattan; Staten Island; the Great Neck infusion center in Nassau County; Port Jefferson Station in Suffolk County; New City in Rockland County; Monroe in Orange County; and Inwood in the Five Towns.
Site of care is now a payer question, not only a convenience question. The UnitedHealthcare commercial site-of-care policy for provider-administered drugs, effective August 1, 2026, names intravenous and subcutaneous immune globulin explicitly and states that "Alternative Sites of Care, such as non-hospital outpatient infusion, physician office, ambulatory infusion suites, or home infusion services are well accepted places of service for medication infusion therapy." Under that UnitedHealthcare policy, hospital outpatient infusion is approved only against specific criteria such as medical instability or severe vascular access problems requiring ultrasound guidance, and approval is capped at six months before reassessment. A freestanding ambulatory center of the kind described on the Prime Infusions IVIG page is the setting that policy prefers.
How does a CIDP patient or referring neurologist start with Prime Infusions?
A patient or caregiver can begin by submitting the IVIG request form, calling Prime Infusions at 718-443-4000, or emailing office@primeinfusions.com. Neurologists and other prescribers can send a CIDP referral through the Prime Infusions referral page, attaching the electrodiagnostic report, the current order and recent office notes. The Prime Infusions team then verifies benefits, submits the prior authorization request and schedules the loading course.
This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation. IVIG products carry an FDA boxed warning for thrombosis and for renal dysfunction and acute renal failure; review the full prescribing information for the product prescribed to you and discuss your individual risk factors with your treating clinician. Coverage and out-of-pocket cost are determined by your health plan.